⌘K
t
GlaxoSmithKline plc reported that Dr H Barron, Chief Scientific Officer and President, R&D, and Mr J Ford, SVP & General Counsel, acquired American Depositary Shares (ADSs) or notional ADSs. These acquisitions resulted from dividend reinvestment within their respective GSK Executive Supplemental Savings Plan and/or GSK 401(k) plan accounts. The transactions took place on November 18, 2021, on the New York Stock Exchange (XNYS), with 2,691.374 ADSs acquired by Dr Barron and 62.798 notional ADSs by Mr Ford, all at a price of $41.5000 per ADS.
| Date | 23 Nov 2021 |
| Time | 15:06:44 |
| Category | Director/PDMR dealings |
| ID | 3167T |
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr H Barron |
|||
|
b) |
Position/status |
Chief Scientific Officer and President, R&D |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$41.5000 |
2,626.374 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-11-18 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr H Barron |
|||
|
b) |
Position/status |
Chief Scientific Officer and President, R&D |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
|||
|
b) |
Nature of the transaction |
Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$41.5000 |
65 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-11-18 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr J Ford |
|||
|
b) |
Position/status |
SVP & General Counsel |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$41.5000 |
62.798 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2021-11-18 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||